International Journal of Biological Sciences-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2233656, encodeId=d4a5223365644, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：3.14 投稿 4.9 大修 6.19 返修，提交原始图像 6.21 条件性接收 6.23 缴费，提交图形摘要，最终版文稿、figure 6.29 proof 7.1 online 效率很高的杂志，主编非常负责，审稿人友好、专业细致, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bad8649258, createdName=ms1000001760489592, createdTime=Mon Oct 28 12:07:41 CST 2024, time=2024-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239850, encodeId=9675223985042, content=在提交稿件时，至少推荐5位潜在的审稿人 该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等 同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论 期刊等影响力和认可度还是比较高的。 有感兴趣的可以多了解，大家可以交流学习一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822131, createdTime=Thu Nov 28 23:39:02 CST 2024, time=2024-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232305, encodeId=94c4223230513, content=偏重的研究方向：肿瘤 经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/f0c95179a35b408c9ca61721649b6f9e/ec3c8babfe2d4b7a9d33693f09273108.jpg, createdBy=5dac5444550, createdName=ms1000002113223257, createdTime=Tue Oct 22 00:35:28 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省)]

2024-11-19 缅怀21世纪来自四川省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？

38 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2233656, encodeId=d4a5223365644, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：3.14 投稿 4.9 大修 6.19 返修，提交原始图像 6.21 条件性接收 6.23 缴费，提交图形摘要，最终版文稿、figure 6.29 proof 7.1 online 效率很高的杂志，主编非常负责，审稿人友好、专业细致, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bad8649258, createdName=ms1000001760489592, createdTime=Mon Oct 28 12:07:41 CST 2024, time=2024-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239850, encodeId=9675223985042, content=在提交稿件时，至少推荐5位潜在的审稿人 该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等 同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论 期刊等影响力和认可度还是比较高的。 有感兴趣的可以多了解，大家可以交流学习一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822131, createdTime=Thu Nov 28 23:39:02 CST 2024, time=2024-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232305, encodeId=94c4223230513, content=偏重的研究方向：肿瘤 经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/f0c95179a35b408c9ca61721649b6f9e/ec3c8babfe2d4b7a9d33693f09273108.jpg, createdBy=5dac5444550, createdName=ms1000002113223257, createdTime=Tue Oct 22 00:35:28 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省)]

2022-02-23 悬崖听风007

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤免疫
经验分享：Received 2021-12-16 from IP
Minor revision 2022-2-8
Received 2022-2-17 from IP
Final accept 2022-2-22
Pre-publish-fee 2022-2-22
投稿到接受2个月零几天，效率杠杠的。感恩。

134 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2233656, encodeId=d4a5223365644, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：3.14 投稿 4.9 大修 6.19 返修，提交原始图像 6.21 条件性接收 6.23 缴费，提交图形摘要，最终版文稿、figure 6.29 proof 7.1 online 效率很高的杂志，主编非常负责，审稿人友好、专业细致, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bad8649258, createdName=ms1000001760489592, createdTime=Mon Oct 28 12:07:41 CST 2024, time=2024-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239850, encodeId=9675223985042, content=在提交稿件时，至少推荐5位潜在的审稿人 该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等 同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论 期刊等影响力和认可度还是比较高的。 有感兴趣的可以多了解，大家可以交流学习一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822131, createdTime=Thu Nov 28 23:39:02 CST 2024, time=2024-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232305, encodeId=94c4223230513, content=偏重的研究方向：肿瘤 经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/f0c95179a35b408c9ca61721649b6f9e/ec3c8babfe2d4b7a9d33693f09273108.jpg, createdBy=5dac5444550, createdName=ms1000002113223257, createdTime=Tue Oct 22 00:35:28 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省)]

2022-12-12 1476a8ddm35暂无昵称来自四川省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：炎症
经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01
动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。

101 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2233656, encodeId=d4a5223365644, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：3.14 投稿 4.9 大修 6.19 返修，提交原始图像 6.21 条件性接收 6.23 缴费，提交图形摘要，最终版文稿、figure 6.29 proof 7.1 online 效率很高的杂志，主编非常负责，审稿人友好、专业细致, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bad8649258, createdName=ms1000001760489592, createdTime=Mon Oct 28 12:07:41 CST 2024, time=2024-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239850, encodeId=9675223985042, content=在提交稿件时，至少推荐5位潜在的审稿人 该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等 同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论 期刊等影响力和认可度还是比较高的。 有感兴趣的可以多了解，大家可以交流学习一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822131, createdTime=Thu Nov 28 23:39:02 CST 2024, time=2024-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232305, encodeId=94c4223230513, content=偏重的研究方向：肿瘤 经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/f0c95179a35b408c9ca61721649b6f9e/ec3c8babfe2d4b7a9d33693f09273108.jpg, createdBy=5dac5444550, createdName=ms1000002113223257, createdTime=Tue Oct 22 00:35:28 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省)]

2024-10-28 ms1000001760489592 来自湖北省

审稿速度:1.0
偏重的研究方向：肿瘤
经验分享：3.14 投稿
4.9 大修
6.19 返修，提交原始图像
6.21 条件性接收
6.23 缴费，提交图形摘要，最终版文稿、figure
6.29 proof
7.1 online
效率很高的杂志，主编非常负责，审稿人友好、专业细致

20 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2233656, encodeId=d4a5223365644, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：3.14 投稿 4.9 大修 6.19 返修，提交原始图像 6.21 条件性接收 6.23 缴费，提交图形摘要，最终版文稿、figure 6.29 proof 7.1 online 效率很高的杂志，主编非常负责，审稿人友好、专业细致, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bad8649258, createdName=ms1000001760489592, createdTime=Mon Oct 28 12:07:41 CST 2024, time=2024-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239850, encodeId=9675223985042, content=在提交稿件时，至少推荐5位潜在的审稿人 该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等 同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论 期刊等影响力和认可度还是比较高的。 有感兴趣的可以多了解，大家可以交流学习一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822131, createdTime=Thu Nov 28 23:39:02 CST 2024, time=2024-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232305, encodeId=94c4223230513, content=偏重的研究方向：肿瘤 经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/f0c95179a35b408c9ca61721649b6f9e/ec3c8babfe2d4b7a9d33693f09273108.jpg, createdBy=5dac5444550, createdName=ms1000002113223257, createdTime=Tue Oct 22 00:35:28 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省)]

2023-05-27 ms2000001238004064 来自广东省

偏重的研究方向：肿瘤;基因功能
经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？

122 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2233656, encodeId=d4a5223365644, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：3.14 投稿 4.9 大修 6.19 返修，提交原始图像 6.21 条件性接收 6.23 缴费，提交图形摘要，最终版文稿、figure 6.29 proof 7.1 online 效率很高的杂志，主编非常负责，审稿人友好、专业细致, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bad8649258, createdName=ms1000001760489592, createdTime=Mon Oct 28 12:07:41 CST 2024, time=2024-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239850, encodeId=9675223985042, content=在提交稿件时，至少推荐5位潜在的审稿人 该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等 同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论 期刊等影响力和认可度还是比较高的。 有感兴趣的可以多了解，大家可以交流学习一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822131, createdTime=Thu Nov 28 23:39:02 CST 2024, time=2024-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232305, encodeId=94c4223230513, content=偏重的研究方向：肿瘤 经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/f0c95179a35b408c9ca61721649b6f9e/ec3c8babfe2d4b7a9d33693f09273108.jpg, createdBy=5dac5444550, createdName=ms1000002113223257, createdTime=Tue Oct 22 00:35:28 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省)]

2024-11-27 541350208 来自重庆

即时影响因子8.2，预测9.8，今年能一区吗？

9 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2233656, encodeId=d4a5223365644, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：3.14 投稿 4.9 大修 6.19 返修，提交原始图像 6.21 条件性接收 6.23 缴费，提交图形摘要，最终版文稿、figure 6.29 proof 7.1 online 效率很高的杂志，主编非常负责，审稿人友好、专业细致, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bad8649258, createdName=ms1000001760489592, createdTime=Mon Oct 28 12:07:41 CST 2024, time=2024-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239850, encodeId=9675223985042, content=在提交稿件时，至少推荐5位潜在的审稿人 该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等 同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论 期刊等影响力和认可度还是比较高的。 有感兴趣的可以多了解，大家可以交流学习一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822131, createdTime=Thu Nov 28 23:39:02 CST 2024, time=2024-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232305, encodeId=94c4223230513, content=偏重的研究方向：肿瘤 经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/f0c95179a35b408c9ca61721649b6f9e/ec3c8babfe2d4b7a9d33693f09273108.jpg, createdBy=5dac5444550, createdName=ms1000002113223257, createdTime=Tue Oct 22 00:35:28 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省)]

2024-09-02 1891e859aem 来自广东省

偏重的研究方向：分子生物学;医学;凋亡
经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审

37 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2233656, encodeId=d4a5223365644, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：3.14 投稿 4.9 大修 6.19 返修，提交原始图像 6.21 条件性接收 6.23 缴费，提交图形摘要，最终版文稿、figure 6.29 proof 7.1 online 效率很高的杂志，主编非常负责，审稿人友好、专业细致, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bad8649258, createdName=ms1000001760489592, createdTime=Mon Oct 28 12:07:41 CST 2024, time=2024-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239850, encodeId=9675223985042, content=在提交稿件时，至少推荐5位潜在的审稿人 该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等 同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论 期刊等影响力和认可度还是比较高的。 有感兴趣的可以多了解，大家可以交流学习一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822131, createdTime=Thu Nov 28 23:39:02 CST 2024, time=2024-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232305, encodeId=94c4223230513, content=偏重的研究方向：肿瘤 经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/f0c95179a35b408c9ca61721649b6f9e/ec3c8babfe2d4b7a9d33693f09273108.jpg, createdBy=5dac5444550, createdName=ms1000002113223257, createdTime=Tue Oct 22 00:35:28 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省)]

2024-11-28 ms2000001788822131 来自上海

在提交稿件时，至少推荐5位潜在的审稿人
该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等
同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论
期刊等影响力和认可度还是比较高的。
有感兴趣的可以多了解，大家可以交流学习一下。

1 0

[GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2233656, encodeId=d4a5223365644, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：3.14 投稿 4.9 大修 6.19 返修，提交原始图像 6.21 条件性接收 6.23 缴费，提交图形摘要，最终版文稿、figure 6.29 proof 7.1 online 效率很高的杂志，主编非常负责，审稿人友好、专业细致, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bad8649258, createdName=ms1000001760489592, createdTime=Mon Oct 28 12:07:41 CST 2024, time=2024-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239850, encodeId=9675223985042, content=在提交稿件时，至少推荐5位潜在的审稿人 该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等 同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论 期刊等影响力和认可度还是比较高的。 有感兴趣的可以多了解，大家可以交流学习一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822131, createdTime=Thu Nov 28 23:39:02 CST 2024, time=2024-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232305, encodeId=94c4223230513, content=偏重的研究方向：肿瘤 经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/f0c95179a35b408c9ca61721649b6f9e/ec3c8babfe2d4b7a9d33693f09273108.jpg, createdBy=5dac5444550, createdName=ms1000002113223257, createdTime=Tue Oct 22 00:35:28 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省)]

2023-08-18 ms2000000311873048 来自湖南省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。

75 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237761, encodeId=f1e1223e76184, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：请问Conditional acceptance后，我上传了图形摘要，高清图片，最终稿件，交了版面费后我只收到了缴费的邮件，我文件收到的邮件没有，怎么知道他们收到了我的最终文件和图片啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45bf2312999, createdName=缅怀21世纪, createdTime=Tue Nov 19 11:30:59 CST 2024, time=2024-11-19, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1196293, encodeId=be65119629314, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫 经验分享：Received 2021-12-16 from IP Minor revision 2022-2-8 Received 2022-2-17 from IP Final accept 2022-2-22 Pre-publish-fee 2022-2-22 投稿到接受2个月零几天，效率杠杠的。感恩。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161008/IMG57F88E7670B394919.jpg, createdBy=4a021962386, createdName=悬崖听风007, createdTime=Wed Feb 23 08:03:34 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105699, encodeId=a05a2105699ff, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：炎症 经验分享：Received: 2022.10.26; Accepted: 2022.12.05; Published: 2023.01.01 动作很快，一个月不到一审结果就回来了，然后花了5天修回，10天左右就接收了，然后5天就出了proof，真是神速。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221212/08d68660ec5249d4951c3cf19104981b/d48862041d924877a2d8ff1dd10a565a.jpg, createdBy=881a5215169, createdName=1476a8ddm35暂无昵称, createdTime=Mon Dec 12 12:53:27 CST 2022, time=2022-12-12, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2233656, encodeId=d4a5223365644, content=审稿速度:1.0 偏重的研究方向：肿瘤 经验分享：3.14 投稿 4.9 大修 6.19 返修，提交原始图像 6.21 条件性接收 6.23 缴费，提交图形摘要，最终版文稿、figure 6.29 proof 7.1 online 效率很高的杂志，主编非常负责，审稿人友好、专业细致, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bad8649258, createdName=ms1000001760489592, createdTime=Mon Oct 28 12:07:41 CST 2024, time=2024-10-28, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2139356, encodeId=cfd42139356ab, content=偏重的研究方向：肿瘤;基因功能 经验分享：这个期刊初次投稿后一直under review ，replace也还在，请问一般要多久编辑才会拒稿呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08728711142, createdName=ms2000001238004064, createdTime=Sat May 27 11:37:14 CST 2023, time=2023-05-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239474, encodeId=3bf522394e4bb, content=即时影响因子8.2，预测9.8，今年能一区吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e94b3000085, createdName=541350208, createdTime=Wed Nov 27 12:46:52 CST 2024, time=2024-11-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2223626, encodeId=512f2223626cd, content=偏重的研究方向：分子生物学;医学;凋亡 经验分享：2024-08-25 投稿，当天active 2024-08-30 replace消失，期待送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34a12034709, createdName=1891e859aem, createdTime=Mon Sep 02 07:52:07 CST 2024, time=2024-09-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2239850, encodeId=9675223985042, content=在提交稿件时，至少推荐5位潜在的审稿人 该期刊涵盖了广泛的生物科学领域，包括生物学、遗传学、生物化学、生态学、微生物学等等 同时接受多种类型的文章，包括原创研究论文、综述文章、短篇通讯和评论 期刊等影响力和认可度还是比较高的。 有感兴趣的可以多了解，大家可以交流学习一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms2000001788822131, createdTime=Thu Nov 28 23:39:02 CST 2024, time=2024-11-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153492, encodeId=73392153492b6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：恶心人的期刊，第一次投2周左右说因为没有找到审稿人就给拒了。然后和编辑battle也没有回信就再投了，这次状态变了但是没给送审又给拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=75, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78186386984, createdName=ms2000000311873048, createdTime=Fri Aug 18 23:35:39 CST 2023, time=2023-08-18, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2232305, encodeId=94c4223230513, content=偏重的研究方向：肿瘤 经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210317/f0c95179a35b408c9ca61721649b6f9e/ec3c8babfe2d4b7a9d33693f09273108.jpg, createdBy=5dac5444550, createdName=ms1000002113223257, createdTime=Tue Oct 22 00:35:28 CST 2024, time=2024-10-22, status=1, ipAttribution=山东省)]

2024-10-22 ms1000002113223257 来自山东省

偏重的研究方向：肿瘤
经验分享：记录一下投稿过程 2024.10.20-提交突然发现这个杂志CAR指数好高，会不会有被踢风险啊，有点害怕，B&P都被on hold了

15 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务